Literature DB >> 27357935

Paying more attention to the 'elephant in the room'.

Ron Borland.   

Abstract

This commentary argues that a nicotine reduction strategy for tobacco control is a secondary strategy to the wider availability of low toxin forms of nicotine to give smokers a viable alternative to cigarettes. Failure to confront the likely reality of continued nicotine use and to make it as low in harm as possible may prolong the tobacco epidemic. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Addiction; Electronic nicotine delivery devices; End game; Harm Reduction; Nicotine

Mesh:

Substances:

Year:  2016        PMID: 27357935     DOI: 10.1136/tobaccocontrol-2016-053150

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  3 in total

1.  Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial.

Authors:  Dorothy K Hatsukami; Xianghua Luo; Laura Dick; Margarita Kangkum; Sharon S Allen; Sharon E Murphy; Stephen S Hecht; Peter G Shields; Mustafa al'Absi
Journal:  Addiction       Date:  2016-11-02       Impact factor: 6.526

2.  Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes.

Authors:  Rachel L Denlinger-Apte; Jennifer W Tidey; Joseph S Koopmeiners; Dorothy K Hatsukami; Tracy T Smith; Lauren R Pacek; F Joseph McClernon; Eric C Donny
Journal:  Tob Control       Date:  2018-11-01       Impact factor: 7.552

3.  Impact of Cigarette Filter Ventilation on U.S. Smokers' Perceptions and Biomarkers of Exposure and Potential Harm.

Authors:  Dana M Carroll; Irina Stepanov; Richard O'Connor; Xianghua Luo; K Michael Cummings; Vaughan W Rees; Warren K Bickel; Micah L Berman; David L Ashley; Maansi Bansal-Travers; Peter G Shields; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-22       Impact factor: 4.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.